12-Mar-2026
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and RxSight (RXST)
TipRanks (Tue, 10-Mar 3:50 AM ET)
RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance
Globe Newswire (Wed, 25-Feb 4:05 PM ET)
RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Globe Newswire (Wed, 11-Feb 4:10 PM ET)
PRNewswire (Thu, 22-Jan 10:00 AM ET)
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
Globe Newswire (Sun, 11-Jan 9:30 AM ET)
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
Globe Newswire (Fri, 2-Jan 4:05 PM ET)
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
Rxsight trades on the NASDAQ stock market under the symbol RXST.
As of March 12, 2026, RXST stock price climbed to $7.64 with 915,187 million shares trading.
RXST has a beta of 1.98, meaning it tends to be more sensitive to market movements. RXST has a correlation of 0.14 to the broad based SPY ETF.
RXST has a market cap of $312.60 million. This is considered a Small Cap stock.
Last quarter Rxsight reported $33 million in Revenue and -$.03 earnings per share. This beat revenue expectation by $5,590 and exceeded earnings estimates by $.25.
In the last 3 years, RXST traded as high as $66.54 and as low as $6.32.
The top ETF exchange traded funds that RXST belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
RXST has underperformed the market in the last year with a price return of -70.7% while the SPY ETF gained +20.5%. RXST has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -39.5% and -3.5%, respectively, while the SPY returned -2.0% and -3.4%, respectively.
RXST support price is $7.09 and resistance is $7.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RXST shares will trade within this expected range on the day.